Results 181 to 190 of about 155,160 (352)

Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT There have only been a limited number of case reports that have described vulval lichen sclerosus in patients receiving immune checkpoint inhibitor (ICI) therapy. We describe 11 cases of vulval lichen sclerosus in patients with melanoma treated with ICIs, and in nine of these cases, the lichen sclerosus symptoms began after ICI commencement ...
Sophie Walter   +9 more
wiley   +1 more source

Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors

open access: yesBritish Journal of Haematology, EarlyView.
Summary Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence ...
Lisa Argnani   +9 more
wiley   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman   +3 more
wiley   +1 more source

Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE‐522 Japan Subgroup Analysis

open access: yesCancer Science, EarlyView.
In the global, phase 3 KEYNOTE‐522 study of high‐risk early‐stage triple‐negative breast cancer (TNBC), neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved efficacy outcomes versus neoadjuvant chemotherapy alone. In this analysis of Japanese participants from KEYNOTE‐522, neoadjuvant pembrolizumab plus chemotherapy ...
Masato Takahashi   +16 more
wiley   +1 more source

Shifts in amino acids profile in chronic pancreatitis. [PDF]

open access: yesPLoS One
Malvik M   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy